BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire • Thursday
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLCGlobeNewsWire • Monday
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/26
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations ConferenceGlobeNewsWire • 11/03/26
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO PriceSeeking Alpha • 10/28/26
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerGlobeNewsWire • 10/22/26
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic CancerGlobeNewsWire • 09/28/26
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung CancerGlobeNewsWire • 09/15/26
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/03/26
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung CancerGlobeNewsWire • 09/01/26
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLCGlobeNewsWire • 08/18/26
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public OfferingGlobeNewsWire • 08/07/26
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline PromiseSeeking Alpha • 08/05/26